IMUGENE LIMITED — Capital/Financing Update 2018

Nov 8, 2018

==> picture [116 x 42] intentionally omitted <==

ASX Announcement

Imugene Receives $1.85 million R&D Tax Incentive

SYDNEY, Australia, 9 November 2018: Imugene Limited (ASX: IMU), an immuno-oncology company is pleased to advise that it has received a research and development (R&D) tax refund of $1.85 million as part of the Australian government’s R&D tax incentive. This incentive recognises the important immuno-oncology research activities undertaken by Imugene during the financial year ended 30 June 2018.

The receipt of the $1.85 million in additional funding will support our commercial and clinical milestones, with the company experiencing its most significant period of R&D expenditure in the September 2018 quarter, with R&D cash outflows of $1.65 million.

The Australian government’s R&D tax incentive encourages companies to engage in R&D programs by providing a refundable tax offset of up to 43.5% for eligible activities.

For further information please contact:

Leslie Chong

Managing Director and Chief Executive Officer

T: +61 458 040 433

Follow us on Twitter @TeamImugene Follow us on Facebook @Imugene Follow us on LinkedIn @Imugene Limited

IMUGENE LIMITED ACN 009 179 551 WWW.IMUGENE.COM info@imugene.com

About Imugene (ASX:IMU)

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Our unique platform technology seeks to harness the body’s immune system to generate antibodies against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody therapies. Our product pipeline includes multiple immunotherapy B-cell vaccine candidates aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene’s immuno-oncology therapies will become a foundation treatment for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.

IMUGENE LIMITED ACN 009 179 551

2